Skip to main content
SpringerLink
Log in

Therapiealgorithmen beim Ovarial-, Zervix- und Endometriumkarzinom

Richtig behandeln in der fortgeschrittenen Situation

  • Gynäkoonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. AWMF-Registernr.: 032-035OL

  2. Gonzáles-Martín A et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2023;34(10):833-48

  3. Burger R et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365(26):2473

  4. Monk BJ et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapyas Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ ENGOT-ov45). J Clin Oncol. 2022;40(34):3952-64

  5. González-Martín A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391-402

  6. Tew WP et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468-93

  7. Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2428

  8. Sznurkowski JJ. To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy? Cancers (Basel). 2023;15(11):2980

  9. Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023; https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5506

  10. Raja FA et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028-34

  11. Harter P. et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23):2123-31

  12. Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):267-76

  13. Tew WP et al. Poly (ADP-Ribose) Polymerase Inhibitors in the management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022;40(33):3878-81

  14. Pujade-Lauraine E et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8

  15. Moore KN et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162-74

  16. S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. AWMF-Registernr.: 032/033OL

  17. Long HJ et al. Randomized Phase III Trial of Cisplatin with or Without Topotecanin Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626-33

  18. Tewari KS et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014;370(8):734-43

  19. Colombo N et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-67

  20. Maio M et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929-38

  21. Bogani G et al. Tisotumab Vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023;47(3):100952

  22. Tewari KS et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386(6):544-55

  23. Oaknin A et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-77

  24. Mirza MR et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-58

  25. Eskander R. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159-70

  26. O'Malley D et al. Pembrolizumab in Patients with Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752-61

  27. Oaknin A et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777

  28. Makker V et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437-48

  29. Meric-Bernstam F et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47-58

Download references

Author information

Authors and Affiliations

  1. Zentrum für ­Hämatologie und Onkologie, Klinik Ottakring, Montleartstraße 37, 1160, Wien, Österreich

    Kathrin Strasser-Weippl

Authors
  1. Kathrin Strasser-Weippl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lea Korber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathrin Strasser-Weippl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strasser-Weippl, K., Korber, L. Therapiealgorithmen beim Ovarial-, Zervix- und Endometriumkarzinom. Fokus Onkol 27, 18–22 (2024). https://doi.org/10.1007/s15015-024-3785-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-024-3785-6

Search

Navigation